(Reuters) – Britain’s AstraZeneca on Friday said that it will begin work with Russia’s Gamaleya Institute to understand whether their two COVID-19 vaccine candidates can be successfully combined.
The Gamaleya Institute is the developer of Russia’s Sputnik V vaccine.
(Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick Graham)
